Compare HUN & ICUI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HUN | ICUI |
|---|---|---|
| Founded | 1970 | 1984 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Medical/Dental Instruments |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 3.2B |
| IPO Year | 2005 | 1992 |
| Metric | HUN | ICUI |
|---|---|---|
| Price | $10.07 | $148.22 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 11 | 5 |
| Target Price | $10.23 | ★ $179.50 |
| AVG Volume (30 Days) | ★ 5.5M | 255.7K |
| Earning Date | 11-06-2025 | 11-06-2025 |
| Dividend Yield | ★ 3.47% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $5,780,000,000.00 | $2,320,363,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.40 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $7.30 | $107.00 |
| 52 Week High | $18.53 | $175.51 |
| Indicator | HUN | ICUI |
|---|---|---|
| Relative Strength Index (RSI) | 54.35 | 62.46 |
| Support Level | $9.95 | $141.39 |
| Resistance Level | $10.40 | $148.95 |
| Average True Range (ATR) | 0.51 | 4.00 |
| MACD | -0.07 | -0.54 |
| Stochastic Oscillator | 24.30 | 82.15 |
Huntsman Corp is a USA-based manufacturer of differentiated organic chemical products. Its product portfolio comprises Methyl diphenyl diisocyanate (MDI), Amines, Maleic anhydride, and Epoxy-based polymer formulations. The company's products are used in adhesives, aerospace, automotive, and construction products, among others. Its operating segments are Polyurethanes, Performance Products, and Materials. It derives the majority of its revenue from the Polyurethanes segment, which includes MDI, polyols, TPU (thermoplastic polyurethane), and other polyurethane-related products. Its geographical segments are the United States & Canada, Europe, Asia-Pacific, and the Rest of the world.
ICU Medical is a California-based pure-play infusion therapy company that provides consumables, systems, and services for virtually every component of the IV continuum of care. ICU has become one of the largest players in its industry following its acquisition of Hospira Infusion Systems from Pfizer in 2017 and Smiths Medical from Smiths Group in 2022. It holds top-tier positions across its three reporting segments: consumables (43% of consolidated revenue), infusion systems (28%), and vital care (29%). The combined entity remains primarily US-focused, generating over 63% of its sales domestically.